99% Purity 53-84-9 Raw Powder Nad NAD;Tirzepatide,Retatrutide,Peptides
126 Inquiries
53-84-9
Pharmaceutical Grade
99%
sz
DL
1g/2g/3g/4g/5g/6g/7g/8g/9g/10g/1kg/10kg
Yes
2027-01-30
Tirzepatide,Retatrutide,Semaglutide,Cagrilintide,NAD+,Bacteriostatic wate
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceNAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
Solid
NAD zwitterion is a NAD. It has a role as a geroprotector. It derives from a deamido-NAD zwitterion. It is a conjugate base of a NAD(+).|A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)|Nadide is a dinucleotide of adenine and nicotinamide. It has coenzyme activity in redox reactions and also acts as a donor of ADP-ribose moieties.Basic Info-
Product Name:
NAD
Other Name:Adenosine 5′-(trihydrogen diphosphate),P′→5′-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium,inner salt;Pyridinium,3-carbamoyl-1-β-D-ribofuranosyl-,hydroxide,5′→5′-ester with adenosine 5′-(trihydrogen pyrophosphate),inner salt;Adenosine 5′-(trihydrogen diphosphate),P′→5′-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium hydroxide,inner salt;Codehydrase I;Codehydrogenase I;Coenzyme I;Diphosphopyridine nucleotide;DPN;Cozymase I;NAD;Nadide;Nicotinamide-adenine dinucleotide;Oxidized diphosphopyridine nucleotide;Adenine-nicotinamide dinucleotide;NAD+;Enzopride;β-NAD;β-Diphosphopyridine nucleotide;β-Nicotinamide adenine dinucleotide;β-NAD+;NSC 20272;CO-I;β-Nicotinamide adenine dinucleotide hydrate;30429-30-2;159929-29-0;1083039-67-1;1354693-98-3
CAS No.:53-84-9
Molecular Formula:C21H27N7O14P2
InChIKeys:InChIKey=BAWFJGJZGIEFAR-NNYOXOHSSA-N
Molecular Weight:663.43
Exact Mass:663.109131
EC Number:200-184-4
NSC Number:757121
DSSTox ID:DTXSID2045236
NCI Thesaurus Code:C87339
HScode:29349990
Categories:
Characteristics-
PSA:
321
XLogP3:-1.29620
Appearance:White Powder
Melting Point:140-142 °C (decomp)
Water Solubility:soluble in water at 50mg/ml
Storage Conditions:2-8°C
Specific rotation:D20 -31.5° (c = 1.2 in water)
Collision Cross Section:226.7 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|227.5 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|222.7 Ų [M+Na]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|223.8 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|230.8 Ų [M+Na-2H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|227 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
Hazard IdentificationClassification of the substance or mixture
Not classified.
GHS label elements, including precautionary statements
Pictogram(s) No symbol. Signal word No signal word
Hazard statement(s) none
Precautionary statement(s) Prevention none
Response none
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Semaglutide,Cagrilintide,NAD+,Bacteriostatic wate
-
Location:
Jinxing Middle Road, Xihu Street, Yuelu District, Changsha City, Hunan Province
-
Payment Terms:
TT against copy of documents,D/P,L/C,TT against B/L draft before shipment
-
Average lead Time:
2 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
-
Inquiry History126 Inquiries
Country Product Purchase Quantity Date Posted
United States
NAD
1 KG Oct 26, 2026
India
NAD
100 G Oct 21, 2026
India
NAD+
20 G Sep 30, 2026
United States
NAD
30 MT Sep 29, 2026
United Arab Emirates
NAD
10 MT Sep 19, 2026
Australia
NAD
50 PCS Sep 16, 2026
United States
NAD
30 MG Sep 1, 2026
Philippines
NAD+
15 KG Sep 1, 2026
Philippines
NAD+
15 KG Aug 31, 2026
United Kingdom
NAD+ 500mg for IV therapy
2 MG Aug 11, 2026
United States
NAD+
1 G Aug 7, 2026
United States
NAD+ 500mg / 1000mg
100 MG Aug 7, 2026
United States
NAD+
1000 MG Aug 4, 2026
South Africa
Nad+
10 MT Jul 27, 2026
United States
β-Nicotinamide adenine dinucleotide
10 G Jul 16, 2026
Poland
Fenbendazole
1 KG Jul 14, 2026
United States
NAD
10 MT Jul 9, 2026
United States
NAD+ 500
10000 MG Jul 2, 2026
United States
Beta-Nicotinamide adenine dinucleotide Nad+
1 MG Jun 18, 2026
Australia
Nad
10 MG Jun 16, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Weight Loss Peptides Cagrilintide Tirz Reta Retatrutide Fox-04-Dir Nad Adipotide Customized Peptides 2mg/5mg
Pharmaceutical Grade / 99%
$85/UNIT FOB
-
-
-
-
China GHK-CU | Cosmetic Peptides | 99% Purity | 50mg 100mg Vials | Lyophilized Powder
Pharmaceutical Grade / 99%
$35-45/G FOB
-
-
-
-
SS-31 99% Purity White Powder raw powder cas 736992-21-5
Pharmaceutical Grade / 99%
$100/G FOB
-
-
-
-
99%Slimming Bodyshaping Peptide Powder 5mg 10mg 15mg 20mg 30mg Anti-Obesity Lyophilized Peptides Semaglutide Weight Loss Peptide
Industrial Grade / 99%
$68/UNIT FOB
-
-
-
-
99% Purity Thymosin Alpha 1 CAS 62304-98-7 Research Reagents Nicotinamide Adenine Dinucleotide Nad Raw Powder Food Additives 99% Nad
Pharmaceutical Grade / 99%
$100/UNIT FOB
-
Hot Related Products
-
β- NMN -
Wholesale 99% Purity Anti-aging β-Nicotinamide Mononucleotide CAS 1094-61-7 NMN Powder -
Factory API Anti-Older CAS 1094-61-7 99.5% Nicotinamide Mononucleotide Nmn Powder -
Wholesale Health Supplements CAS 1094-61-7 Natural Beta Nicotinamide Mononucleotide Nmn -
β-Nicotinamide Mononucleotide CAS:1094-61-7 -
More than 15 years GMP Factory Suppy 99.5% Nicotinamide ribonucleotide Medical Grade CAS1094-61-7 -
β-Nicotinamide MononucleotideBeta-Nicotinamide Mononucleotide -
Top Quality Factory Supply Pure 99% nicotinamide mononucleotide powder API powder NMN -
In tock, β-Nicotinamide Mononucleotide,NMN, -
99% High Purity Anti-aging NMN Raw Powder β-Nicotinamide Mononucleotide CAS 1094-61-7